Analysts

Merck Amgen

Analysts Ritholtz Wealth Management highlight Merck & Co., Inc. (MRK) and Amgen (AMGN) as biotech stocks show significant breakout potential

Merck's recent Phase 3 trial success in combination therapy has significantly boosted its stock, indicating a positive shift in investor sentiment towards its pipeline. This development, along with Amgen's strong performance, highlights a broader resurgence in the biotech sector, which could attract more investor interest.